| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $8.6M | +249.5% |
| R&D Expense | $152.4M | +75.7% |
| SG&A Expense | $56.3M | +33.9% |
| Operating Income | -$200.2M | -58.4% |
| Net Income | -$182.8M | -48.3% |
| EPS (Basic) | -$10.21 | +45.4% |
| EPS (Diluted) | -$10.21 | +45.4% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $215.4M | +164.9% |
| Current Assets | $404.4M | +376.4% |
| Total Assets | $483.1M | +449.3% |
| Current Liabilities | $37.5M | +138.4% |
| Total Liabilities | $37.7M | +106.0% |
| Stockholders' Equity | $445.4M | +539.4% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$131.8M | -18.6% |
| Capital Expenditures | $0 | -100.0% |
| Investing Cash Flow | -$248.5M | -738.0% |
| Financing Cash Flow | $514.3M | +459.8% |
| Free Cash Flow | -$131.8M | -18.5% |